REG - CVS Group plc - Update on move to the Main Market

CVSAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251211:nRSK0997La&default-theme=true

RNS Number : 0997L  CVS Group plc  11 December 2025

For Immediate
Release
                          11 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

 

 

Update on move to the Main Market

 

CVS, the UK listed veterinary group and a leading provider of veterinary
services, today provides an update on the proposed admission of the Company's
entire issued ordinary share capital to the equity shares (commercial company)
category ("ESCC") of the Official List and to trading on the main market for
listed securities (the "Main Market") of the London Stock Exchange plc
("Admission").

 

Further to the announcement on the 24 October 2025, the Board now expects that
(i) Admission will take place at 8.00 a.m. on 29 January 2026; and (ii) the
ordinary shares will be cancelled from trading on AIM at 8.00 a.m. on 29
January 2026. The last day of trading in the ordinary shares on AIM is
therefore expected to be 28 January 2026. Admission will be effected through
an introduction of the Company's existing ordinary shares at which time the
Company's admission to AIM is expected to be cancelled. Accordingly, the
Company hereby gives notice of the intended cancellation of trading of its
Ordinary Shares on AIM in accordance with Rule 41 of the AIM Rules for
Companies. Such cancellation is not subject to shareholder approval.

 

Admission remains subject to a number of conditions, including (i) the
approval by the FCA of a Prospectus and the ordinary shares being admitted by
the FCA to the ESCC segment of the Official List; and (ii) admission by the
London Stock Exchange to trading of the ordinary shares on the Main Market.

 

Shareholders should note that the Company's shares will no longer be traded on
AIM with effect from Admission and should take their own financial and
taxation advice regarding the consequences of Admission.

 

Berenberg is acting as Sponsor exclusively to the Company and no one else in
connection with the proposed Admission.

 

Contacts

CVS Group
plc
via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Berenberg (Sponsor & Joint
Broker)
+44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Peel Hunt LLP (Nominated Adviser & Joint
Broker)
          +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Camarco (Financial
PR)
                                cvsg@camarco.co.uk

Ginny Pulbrook
 
                                              +44
(0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in
the UK and Australia.  CVS is focused on providing high-quality clinical
services to its clients and their animals, with outstanding and dedicated
clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories,
including specialist referral hospitals and dedicated out-of-hours sites.
Alongside the core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties) and an online retail
business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and
c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDDBBDDUSBDGUG



            Copyright 2019 Regulatory News Service, all rights reserved